617,824 Shares in Johnson & Johnson $JNJ Purchased by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. has made a new investment of $102.46 million in Johnson & Johnson, acquiring 617,824 shares of stock in the 1st quarter.
• Johnson & Johnson's recent quarterly earnings report showed earnings per share of $2.77, exceeding analysts' estimates of $2.68, with revenue at $23.74 billion.
• The company declared a quarterly dividend of $1.30 per share, with an annualized dividend yield of 2.9%, reflecting a payout ratio of 55.61%.

T. Rowe Price Investment Management Inc. purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 617,824 shares of the company's stock, valued at approximately $102,460,000.

A number of other hedge funds have also bought and sold shares of the business. Elios Financial Group Inc. lifted its holdings in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after acquiring an additional 66 shares during the period. Atlantic Family Wealth LLC raised its stake in shares of Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after buying an additional 67 shares during the period. MBA Advisors LLC raised its stake in shares of Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after buying an additional 68 shares during the period. Sovereign Financial Group Inc. raised its stake in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc raised its stake in shares of Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after buying an additional 69 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded up $0.1680 during mid-day trading on Friday, hitting $179.0980. The company had a trading volume of 9,523,149 shares, compared to its average volume of 8,494,048. The company has a market capitalization of $431.33 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 2.28 and a beta of 0.41. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock's 50-day moving average price is $163.48 and its 200-day moving average price is $159.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the business earned $2.82 earnings per share. The firm's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

Several analysts have issued reports on JNJ shares. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Royal Bank Of Canada boosted their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Finally, Barclays lifted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.